Key Takeaways Exact Sciences is driving growth through Cologuard, Oncotype DX and new product launches.EXAS targets 15% revenue growth, $150M savings by 2026 and stronger operating margins.Macroeconomic pressures and fierce competition remain key challenges for Exact Sciences.Exact Sciences Corporation (EXAS) is well-poised to grow in the coming quarters, courtesy of the ongoing momentum in its Cologuard and Oncotype DX tests. The company continues to invest in its pipeline to develop innovative solutions f ...